exRNAdisease

Entry Detail

---



General Information

Database ID: exR0356533 RNA Name: hsa-miR-200c-3p RNA Type: miRNA Chromosome: chr12 Starnd: + Coordinate: Start Site(bp): 6963742 End Site(bp): 6963764 External Links: hsa-miR-200c-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE98181 Description: Circulating miRNA profiles from serum of women at high-risk for breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: NA Case Sample: Breast Cancer Control Sample: Healthy Number of Case: 24 Number of Control: 24 Number of Samples: 48

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CHD9 chr16 53055033 53329150 + CTNND1 chr11 57753243 57819546 + FOXP1 chr3 70952817 71583993 - GPR180 chr13 94601857 94634661 + KLF3 chr4 38664197 38701517 + NRBP1 chr2 27427790 27442259 + NRIP1 chr21 14961235 15065936 - PTP4A1 chr6 63521746 63583436 + RBM12 chr20 35648925 35664956 - SLC35B4 chr7 134289332 134316930 - SMAD7 chr18 48919853 48952052 - SRP72 chr4 56467617 56503681 + THAP2 chr12 71664301 71680644 + XPO4 chr13 20777329 20903048 - AC008982.1 chr19 38817471 38840178 - CASD1 chr7 94509219 94557019 + CEBPZ chr2 37201612 37231596 - ECH1 chr19 38815422 38831841 - PSMB2 chr1 35599541 35641526 - SNX5 chr20 17941597 17968980 - SZRD1 chr1 16352575 16398145 + WDR13 chrX 48590042 48608869 + ZNF217 chr20 53567065 53609907 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001731 chr7 100731990 100738448 + hsa_circ_0001486 chr5 56526672 56527148 + hsa_circ_0000552 chr14 71880664 71948928 + hsa_circ_0001358 chr3 169694733 169706147 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC024940.6 chr12 31280422 31280895 - AC092295.2 chr19 36489649 36491040 + AC116913.1 chr15 66488658 66492109 - AF254983.1 chr21 10482738 10605716 + AL049840.4 chr14 103694516 103695050 - LINC00667 chr18 5237826 5290608 + MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + SNHG22 chr18 49814023 49851059 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE98181 Sample Source: Blood Source Fraction: Serum Platform: GPL21572 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 2546 Sample treatment protocol: Serum is obtained from coagulated whole blood samples by centrifugation at 3000 rpm for 10 minutes. RNA Extract protocol: RNA was isolated from a 200ul serum aliquot using the miRNeasy Serum Plasma kit with ce-miR-39 spike-in (QIAGEN), QIAcube (QIAGEN) automation, and eluted with 14uL of nuclease-free water. RNA library preparation protocol: Exactly 8ul of RNA was tagged with a Poly-A tail, using an ATP driven reaction from the Affymetrix® FlashTag™ Biotin HSR RNA Labeling Kit.

Reference

PMID: 29348816 Title: Development of a predictive miRNA signature for breast cancer risk among high-risk women. Author: Farina NH, Ramsey JE, Cuke ME, Ahern TP, Shirley DJ, Stein JL, Stein GS, Lian JB, Wood ME Journal: Oncotarget. 2017 Nov 28;8(68):112170-112183. Description: We evaluated the ability of C-miRNAs to identify women most likely to develop breast cancer by profiling miRNA from serum obtained long before diagnosis.